Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 10:15:1366489.
doi: 10.3389/fimmu.2024.1366489. eCollection 2024.

Potential application mechanism of traditional Chinese medicine in treating immune checkpoint inhibitor-induced colitis

Affiliations
Review

Potential application mechanism of traditional Chinese medicine in treating immune checkpoint inhibitor-induced colitis

Jing Wang et al. Front Immunol. .

Abstract

Cancer ranks among the foremost causes of mortality worldwide, posing a significant threat to human lives. The advent of tumor immunotherapy has substantially transformed the therapeutic landscape for numerous advanced malignancies, notably non-small cell lung cancer and melanoma. However, as immune checkpoint inhibitors (ICIs) are increasingly applied in clinical settings, a spectrum of undesired reactions, termed immune-related adverse events (irAEs), has emerged. These adverse reactions are associated with immunotherapy and can result in varying degrees of harm to the human body. Among these reactions, Immune checkpoint inhibitor-induced colitis (ICIIC) stands out as one of the most prevalent clinical adverse events. In contemporary times, traditional Chinese medicine (TCM) has demonstrated remarkable efficacy in addressing various maladies. Consequently, investigating the potential application and mechanisms of Chinese medicine in countering immune checkpoint inhibitor-induced colitis assumes significant importance in the treatment of this condition.

Keywords: immune; immune checkpoint inhibitor-induced colitis; mechanisms; potential application; traditional Chinese medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Mechanism of TCM in the treatment of immune checkpoint inhibitor-induced colitis: In this condition, overactivated T cells lead to intestinal epithelial inflammation, mucosal damage, barrier breakdown, and an imbalance of inflammatory factors. TCM can alleviate colitis symptoms by increasing anti-inflammatory factors, reducing pro-inflammatory factors, and altering intestinal flora and metabolites. This mechanism illustrates how TCM can effectively treat immune checkpoint inhibitor-induced colitis.
Figure 2
Figure 2
Mechanism by which TCM affects immune checkpoint inhibitor-induced colitis from a TCM standpoint: TCM helps the body achieve a balance between healthy qi and pathogenic qi by eliminating pathogenic factors.

Similar articles

Cited by

References

    1. Li Y, Kang X, Wang H, Guo X, Zhou J, Duan L. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. Thorac Cancer. (2020) 11:829–34. doi: 10.1111/1759-7714.13338 - DOI - PMC - PubMed
    1. Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology. (2017) 6(6):e1344805. doi: 10.1080/2162402X.2017.1344805 - DOI - PMC - PubMed
    1. Bishay K, Tandon P, Bourassa-Blanchette S, Laurie SA, McCurdy JD. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Curr Oncol. (2020) 27:e486–e94. doi: 10.3747/co.27.6251 - DOI - PMC - PubMed
    1. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. (2012) 30:2691–7. doi: 10.1200/JCO.2012.41.6750 - DOI - PubMed
    1. Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, et al. . Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. (2019) 8:e1524695. doi: 10.1080/2162402X.2018.1524695 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources